Chemical conjugates of Evans Blue derivatives and their use in the production of long-acting therapeutics
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsXiaoyuan Chen, Lixin Lang, Gang Niu
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a compound of Formula I or Formula II or a pharmaceutically acceptable ester, amide, solvate, or salt thereof, or a salt of such an ester or amide or a solvate of such an ester amide or salt: Formula I Formula II The compounds of Formula I may be covalently bonded to a therapeutic compound or fragment thereof to provide a compound of Formula II and thereby extend the half-life of the therapeutic compound. The invention is also directed to pharmaceutical compositions of the disclosed compounds, as well as their use in the diagnosis or treatment of diseases.
Claims33
A compound of Formula I or a pharmaceutically acceptable ester, amide, solvate, or salt thereof, or a salt of such an ester or amide or a solvate of such an ester, amide, or salt,
- wherein:
- R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11 are chosen independently from hydrogen, halogen, hydroxyl, cyano, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkyl, and C1-C6haloalkoxy;
- and
- L1 is —(CH2)m— wherein m is an integer from 0 to 12, wherein each CH2 can be individually replaced with —O—, —NH(CO)—, or —(CO)NH—, providing no two adjacent CH2 groups are replaced, and wherein L1 is optionally substituted with 1 substituent -A-B—X, wherein A is a bond, —NH—, —NH(CO)—, —(CO)NH—, B is C0-12alkyl, or phenylC0-12alkyl, and X is a hydrogen, halogen or an Sn derivative, and wherein when m is 0, the compound additionally comprises a radionuclide.
A compound of Formula II or a pharmaceutically acceptable ester, amide, solvate, or salt thereof, or a salt of such an ester or amide or a solvate of such an ester amide or salt,
- wherein:
- R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11 are chosen independently from hydrogen, halogen, hydroxyl, cyano, C1-C6alkoxy, C1-C6haloalkyl, and C1-C6haloalkoxy;
- L1 is —(CH2)m— wherein m is an integer from 0 to 12, wherein each CH2 can be individually replaced with —O—, —NH(CO)—, or —(CO)NH—, providing no two adjacent CH2 groups are replaced, and wherein L1 is optionally substituted with 1 substituent which is -A-B—X, wherein A is a bond, —NH—, —NH(CO)—, —(CO)NH—, B is C0-12alkyl, or phenylC0-12alkyl, and X is a hydrogen, halogen or an Sn derivative;
- L2 is —(CH2)r— wherein r is an integer from 0 to 12, wherein each CH2 can be individually replaced with —O—, —NH(CO)—, or —(CO)NH—, providing no two adjacent CH2 groups are replaced;
- and
- R is a therapeutic compound.
A pharmaceutical composition comprising the compound of Formula II together with a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.